Doseology Sciences Inc. (CSE: MOOD | OTCQB: DOSEF | FSE: VU70), a Kelowna, British Columbia-based consumer product innovation company specialising in oral pouch and functional stimulant product technologies, announced on October 29, 2026 that it missed the prescribed deadline to file its annual audited financial statements for the year ended June 30, 2026. The company applied for and received a Management Cease Trade Order (MCTO) under National Policy 12-203, which restricts trading by insiders and employees while allowing common shareholders to continue trading. The company attributes the delay solely to its auditor requiring additional time to complete the audit, citing no unresolved accounting matters or outstanding information requests.

Key Points

  • Doseology Sciences Inc. (CSE: MOOD | OTCQB: DOSEF | FSE: VU70) is a Kelowna, B.C.-based oral pouch and functional stimulant product company
  • The company missed its October 28, 2026 annual filing deadline, triggering a Management Cease Trade Order under National Policy 12-203
  • The auditor is expected to require approximately two additional weeks; the company targets filing Annual Filings on or before November 15, 2026
  • Investors should monitor the company's bi-weekly default status reports issued under NP 12-203 compliance obligations

Auditor Timeline Behind Doseology's Annual Filing Delay

Doseology Sciences confirmed the delay in filing its annual audited financial statements, management's discussion and analysis, and CEO/CFO certifications for the fiscal year ended June 30, 2026 was not caused by unresolved accounting issues, management delays, or outstanding information requests. The release states the company's auditor requires approximately two additional weeks to complete the audit. As a result, Doseology anticipates filing all required Annual Filings on or before November 15, 2026, and says staff is working diligently alongside its auditors to meet that target date.

How the MCTO Protects General Shareholders of MOOD

Rather than subjecting all shareholders to a full cease trade order, Doseology applied for and received an MCTO under National Policy 12-203. This regulatory mechanism restricts trading in the company's securities by insiders and employees only, permitting general investors holding common shares to continue transacting in the market. The company confirmed it is not subject to insolvency proceedings and disclosed no additional material information concerning its affairs beyond what was contained in the announcement. The immediate share price impact was not clear from available public information.

Bi-Weekly Reporting Obligations During Default Period

Under NP 12-203 requirements, Doseology committed to issuing bi-weekly default status reports for as long as it remains in default of its financial statement filing obligations. Those reports must include any material changes to information in this release, actions taken to remedy the default, details of any further defaults, and any other material company information not previously disclosed. The company's compliance with this alternative information guideline framework will be a key area investors may be watching as the November 15, 2026 target filing date approaches.

Doseology's Focus on the Oral Pouch Consumer Market

Doseology Sciences specialises in pouch-based oral stimulant and cognitive support products, operating in a sector the company describes as one of the most dynamic and high-growth areas in modern functional consumer products. The oral stimulant pouch format is smokeless and vapour-free, offering consumers a discreet alternative to combustible tobacco or vape delivery methods. The company trades on three exchanges — the CSE, OTCQB, and Frankfurt Stock Exchange — reflecting its cross-border investor profile within this expanding consumer product category.